Tech Company Financing Transactions
BridGene Biosciences Funding Round
BridGene Biosciences secured a $38.5 million Series B funding round on 7/27/2022. Investors included Dyee Capital and Junson Capital.
Transaction Overview
Company Name
Announced On
7/27/2022
Transaction Type
Venture Equity
Amount
$38,500,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the offering will be used to further develop BridGene's chemoproteomic platform IMTAC, which enables the screening of small molecules against the whole proteome or against a prioritized target in live cells to discover drug candidates for high value and traditionally undruggable targets that drive diseases, including cancers.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
75 Nicholson Ln.
San Jose, CA 95134
USA
San Jose, CA 95134
USA
Phone
Website
Email Address
Overview
BridGene Biosciences is a biotechnology company focusing on discovering and developing innovative small molecules that drug high value yet previously undruggable targets, providing new paths to treat diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ping Cao
Executive Vice President
Irene Yuan
VP - Bus. Development
Linda Pullan
Browse more venture capital transactions:
Prev: 7/27/2022: Packworks venture capital transaction
Next: 7/27/2022: Menusifu venture capital transaction
Share this article
About Database of VC Transactions
We do our best to record tech company VC transactions. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs